Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma.
It is unclear how the immune response controls human herpesvirus 8 (HHV8; also known as Kaposi sarcoma-associated herpesvirus [KSHV]) replication and thereby prevents Kaposi sarcoma (KS). We compared CD8 T-cell responses to HHV8 latent (K12) and lytic (glycoprotein B, ORF6, ORF61, and ORF65) antigens in patients who spontaneously controlled the infection and in patients with posttransplantation, AIDS-related, or classical KS. We found that anti-HHV8 responses were frequent, diverse, and strongly differentiated toward an effector phenotype in patients who controlled the infection. Conversely, HHV8-specific CD8 cells were very rare in patients who progressed to KS, and were not recruited to the tumoral tissue, as visualized by in situ tetramer staining of KS biopsies. Last, HHV8-specific CD8 T cells were observed in a seronegative recipient of an HHV8infected graft who remained persistently aviremic and antibody negative, suggesting that specific cytotoxic T lymphocytes (CTLs) may provide protection from persistent HHV8 infection. These results support the crucial role of cellular immune responses in controlling HHV8 replication, in preventing malignancies in latently infected subjects, and in conferring genuine resistance to persistent infection. They may also have important implications for the design of prophylactic and therapeutic HHV8 vaccines, and for adoptive immunotherapy of KS.
Lambert
Marion
M
INSERM U561, Hôpital St-Vincent de Paul, 75014 Paris, France.
Gannagé
Monique
M
Karras
Alexandre
A
Abel
Michal
M
Legendre
Christophe
C
Kerob
Delphine
D
Agbalika
Felix
F
Girard
Pierre-Marie
PM
Lebbe
Celeste
C
Caillat-Zucman
Sophie
S
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000276:immunology* / Q000473:pathology / Q000821:virology; D000368:Aged; D000957:Antigens, Viral, Tumor / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D005260:Female; D019288:Herpesvirus 8, Human / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D008297:Male; D008875:Middle Aged; D009365:Neoplasm Regression, Spontaneous / Q000276:immunology / Q000473:pathology; D012514:Sarcoma, Kaposi / Q000276:immunology* / Q000473:pathology / Q000628:therapy / Q000821:virology; D019737:Transplants / Q000009:adverse effects; D014779:Virus Replication / Q000276:immunology*
D000957:Antigens, Viral, Tumor; D019496:Cancer Vaccines; D022283:Herpesvirus Vaccines